Melanoma is typically the most serious type of skin cancer diagnosed but new research has raised concerns about other high-risk forms of non-melanoma skin cancer.
2024
Adjuvant Dabrafenib Plus Trametinib for Stage III BRAF V600–Mutated Melanoma: Final Results of the COMBI-AD Trial
Georgina V. Long, MD, PhD, of the Melanoma Institute Australia and the University of Sydney, and colleagues reported the final follow-up analysis of the phase III COMBI-AD trial at the 2024 ASCO Annual Meeting (Abstract 9500) and published their findings in The New England Journal of Medicine.
Q&A: Researchers discuss identifying potential new protein targets for melanoma therapeutics
Yu-Hwa Huang, Ph.D. and Charles Yoon, MD, of the Department of Medicine and Department of Surgery at Brigham and Women’s Hospital respectively, are co-lead authors of a paper titled “High-dimensional mapping of human CEACAM1 expression on immune cells and association with melanoma drug resistance," published in Communications Medicine. In this article, they discuss their findings.
Enhance early detection of melanoma with liquid lenses
Melanoma, a deadly form of skin cancer, poses a significant global health concern.